RhumbLine Advisers
HUMA icon

RhumbLine Advisers’s Humacyte HUMA Stock Holding History

RhumbLine Advisers’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.7K Sell
71,441
-103,108
-59% -$95.5K ﹤0.01% 3663
2026
Q1 		$106K Sell
174,549
-3,616
-2% -$3.76K ﹤0.01% 3386
2025
Q4 		$171K Buy
178,165
+2,686
+2% +$3.8K ﹤0.01% 3246
2025
Q3 		$305K Sell
175,479
-2,144
-1% -$4.2K ﹤0.01% 2982
2025
Q2 		$371K Buy
177,623
+60,059
+51% +$115K ﹤0.01% 2864
2025
Q1 		$200K Buy
117,564
+3,109
+3% +$11.7K ﹤0.01% 3101
2024
Q4 		$578K Buy
114,455
+5,005
+5% +$24.8K ﹤0.01% 2582
2024
Q3 		$595K Sell
109,450
-1,469
-1% -$9.69K ﹤0.01% 2585
2024
Q2 		$532K Buy
110,919
+51,858
+88% +$270K ﹤0.01% 2636
2024
Q1 		$184K Buy
59,061
+2,186
+4% +$7.35K ﹤0.01% 3223
2023
Q4 		$162K Buy
56,875
+1,930
+4% +$4.95K ﹤0.01% 3282
2023
Q3 		$161K Buy
54,945
+1,433
+3% +$4.74K ﹤0.01% 3270
2023
Q2 		$153K Buy
53,512
+4,400
+9% +$15.9K ﹤0.01% 3373
2023
Q1 		$152K Sell
49,112
-2,194
-4% -$6.24K ﹤0.01% 2800
2022
Q4 		$108K Buy
51,306
+28,522
+125% +$86.6K ﹤0.01% 2895
2022
Q3 		$74K Buy
22,784
+1,354
+6% +$5.19K ﹤0.01% 3028
2022
Q2 		$69K Buy
+21,430
New +$119K ﹤0.01% 3048

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

RhumbLine Advisers's HUMA Position: Q2 2026 in Review

RhumbLine Advisers reduced its Humacyte (HUMA) stake by 59% in Q2 2026, selling an estimated $95.5K and leaving 71,441 shares worth $55.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3663.

RhumbLine Advisers first reported a position in HUMA in Q2 2022 and has held it in 17 quarters since. The position peaked at $595K in Q3 2024. 164 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • RhumbLine Advisers held 71,441 shares of Humacyte worth $55.7K as of Q2 2026.
  • RhumbLine Advisers sold 103,108 Humacyte shares in Q2 2026, an estimated $95.5K.
  • Humacyte made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3663 holding.
  • RhumbLine Advisers first reported a position in Humacyte in Q2 2022 and has held it in 17 quarters since.
  • RhumbLine Advisers's Humacyte position peaked at $595K in Q3 2024.
  • 164 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.